New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 1, 2021 - Merck announced that the company plans to voluntarily withdraw the accelerated approval indication for Keytruda (pembrolizumab).
Download PDF
Return to publications
